Literature DB >> 32051196

Total Antioxidant Capacity and Pancreatic Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Guo-Chao Zhong1, Jian-Yuan Pu1, Yi-Lin Wu1, Zhu-Jun Yi1, Lun Wan2, Kang Wang3, Fa-Bao Hao4, Yong Zhao5, Jian-Ping Gong6.   

Abstract

BACKGROUND: Total antioxidant capacity (TAC) reflects an individual's overall antioxidant intake. We sought to clarify whether higher TAC is associated with lower risks of pancreatic cancer incidence and mortality in the U.S. general population.
METHODS: A total of 96,018 American adults were identified from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. A ferric-reducing ability of plasma score was used to reflect an individual's TAC intake from diet and/or supplements. Cox regression was used to calculate hazard ratios (HR) for pancreatic cancer incidence, and competing risk regression was used to calculate subdistribution HRs for pancreatic cancer mortality. Restricted cubic spline regression was used to test nonlinearity.
RESULTS: A total of 393 pancreatic cancer cases and 353 pancreatic cancer-related deaths were documented. Total (diet + supplements) TAC was found to be inversely associated with pancreatic cancer incidence (HR quartile 4 vs. quartile 1 = 0.53; 95% confidence interval, 0.39-0.72; P trend = 0.0002) and mortality (subdistribution HR quartile 4 vs. quartile 1 = 0.52; 95% confidence interval 0.38-0.72; P trend = 0.0003) in a nonlinear dose-response manner (all P nonlinearity < 0.01). Similar results were observed for dietary TAC. No association of supplemental TAC with pancreatic cancer incidence and mortality was found.
CONCLUSIONS: In the U.S. general population, dietary but not supplemental TAC level is inversely associated with risks of pancreatic cancer incidence and mortality in a nonlinear dose-response pattern. IMPACT: This is the first prospective study indicating that a diet rich in antioxidants may be beneficial in decreasing pancreatic cancer incidence and mortality. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32051196     DOI: 10.1158/1055-9965.EPI-19-1511

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and pancreatic cancer incidence and mortality: A prospective cohort study.

Authors:  Zhi-Qing Zhang; Qu-Jin Li; Fa-Bao Hao; You-Qi-Le Wu; Shan Liu; Guo-Chao Zhong
Journal:  Cancer Med       Date:  2020-07-27       Impact factor: 4.452

2.  Dysmetabolisms Can Affect Total Antioxidant Capacity (TAC) of Human Plasma: Determination of Reference Intervals of TAC by Way of CUPRAC-BCS Method.

Authors:  Enrico Prenesti; Silvia Berto; Fabio Gosmaro; Marco Bagnati; Giorgio Bellomo
Journal:  Antioxidants (Basel)       Date:  2021-01-05

3.  Biomolecules Responsible for the Total Antioxidant Capacity (TAC) of Human Plasma in Healthy and Cardiopathic Individuals: A Chemical Speciation Model.

Authors:  Enrico Prenesti; Silvia Berto; Fabio Gosmaro; Marco Bagnati; Giorgio Bellomo
Journal:  Antioxidants (Basel)       Date:  2021-04-23

4.  Dietary Total Antioxidant Capacity and Risk of Polycystic Ovary Syndrome: A Case-Control Study.

Authors:  Nargeskhatoon Shoaibinobarian; Ghazaleh Eslamian; Morvarid Noormohammadi; Shirin Malek; Shayesteh Rouhani; Seyedeh Nooshan Mirmohammadali
Journal:  Int J Fertil Steril       Date:  2022-08-21

5.  Fried food consumption and the risk of pancreatic cancer: A large prospective multicenter study.

Authors:  Guo-Chao Zhong; Qian Zhu; Jian-Ping Gong; Dong Cai; Jie-Jun Hu; Xin Dai; Jun-Hua Gong
Journal:  Front Nutr       Date:  2022-07-22

Review 6.  The interplay between reactive oxygen species and antioxidants in cancer progression and therapy: a narrative review.

Authors:  Osama Hussein Bekhet; Mohamed Elsayed Eid
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.